CarthaGenetics

CarthaGenetics is a Swiss-based consulting and service company specializing in the development and commercialization of orphan drugs and advanced therapies. Founded in 2004, the company focuses on the European, Turkish, and North African markets, providing expertise in patient identification, early access programs (EAPs), and regulatory strategy. They leverage a strong network of medical specialists to accelerate clinical trial enrollment and facilitate access to innovative treatments for rare genetic disorders. Additionally, CarthaGenetics offers specialized services for the development of orphan drug biosimilars in regions where market exclusivity does not apply.